
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
Keywords: Bevacizumab; Colorectal cancer; FOLFOXIRI; UGT1A1;